Insuer Challenges Amgen Over Patent-Application Monopoly — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Amgen is defending against litigation brought by a large health insurer arguing that its acquisition of a drug patent application is an unfair attempt to maintain monopoly power on a medicine
- The Federal Trade Commission has weighed in on the side of payers and consumers, arguing the patent maneuver deserves antitrust scrutiny
- The case outcome could place broader pharmaceutical patent deals under increased legal challenge at a time when patent strategies are frequently cited as tools drugmakers use to keep drug prices high
- The litigation centers on a nuanced legal question: at what point does buying a patent application cross from legitimate business conduct into monopolistic behavior
- Drugmakers are routinely accused of manipulating the U.S. patent system to crowd out generic and biosimilar rivals — context framing this specific dispute
Why it matters: If the court rules that buying a patent application can extend monopoly power, drugmakers face wider legal exposure for a deal-making strategy used to delay competition and sustain high prices. The FTC's unexpected siding with payers signals rising federal appetite to challenge these patent maneuvers as antitrust violations.
Ask SkimNews
